Max Kates, Co Director, Greenberg Bladder Cancer Institute at Johns Hopkins Medicine, shared on X:
“Neoadjuvant MIBC Trials: KEYNOTE-866 (pembro) and ENERGIZE (nivo)negative.
NIAGARA (durva) stands alone. Adjuvant is split too. ICI benefit in MIBC is real but marginal, and likely lives in a subset we have yet to identify.
Utilit of chemo+IO less clear in EVP era.”
You can also read:
